Risk Assessment for Venous Thrombosis in Lymphoma and Emerging Biomarkers

Although the primary endpoint did not reach statistical significance in the intention-to-treat analysis (6.0% vs. 8.8%), rivaroxaban significantly reduced thromboembolic events during the treatment period, with low rates of major bleeding (2.0% vs. 1.0%).

also in 111,027 other papers